Treace Medical Q2 revenue $20.7M (+167% YoY); raises FY2021 guidance to $90-95M

TREACE MEDICAL CONCEPTS, INC.

2022-Q2 EPS reported -$0.18 revenue$39,361,000

Revenue $20.7M, up 167% from $7.7M in Q2 2020; gross margin improved to 80.9% from 73.1%.
Net loss of ($5.1M) or ($0.10) per share, compared to ($2.1M) loss a year ago.
Cash and equivalents $119.6M, including $107.6M from April 2021 IPO.
FY2021 revenue guidance raised to $90-95M (57-65% growth) from prior $87-92M.
ALIGN3D clinical study shows positive radiographic and patient-reported outcomes from 6 weeks to 12 months.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.